Trial Profile
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Troriluzole (Primary)
- Indications Spinocerebellar ataxias
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals
- 13 Apr 2024 According to Biohaven Therapeutics media release, data from the study will be presented as both oral and poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting
- 23 Jan 2024 Planned End Date changed from 22 Dec 2024 to 1 Oct 2025.
- 27 Jul 2023 According to a Biohaven Pharmaceuticals media release, troriluzole was submitted under a 505(b)(2) application.